Type 2 Diabetes Clinical Trial
Official title:
A Pilot, Randomised, Double-blind, Cross-over Study to Assess the Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy
Aspirin is commonly used for treatment of painful and inflammatory diseases and in the
prevention of the cardiovascular disease. A major drawback of aspirin treatment is the well
recognized gastrointestinal toxicity. Recent research indicate that coupling a nitric oxide
(NO)derivate to the aspirin moiety retains its therapeutic effects while avoiding its
undesirable gastrointestinal side effects. NO has cytoprotective effects, such as blood flow
modulation, mucus release and repair of mucosal injury. NCX4016, a NO-releasing derivative
of acetylsalicilic acid, has been shown to retain the analgesic, anti-inflammatory and
antithrombotic activity of aspirin, but with less gastrointestinal toxicity. In addition,
preliminary data suggested that NCX4016 may restore insulin sensitivity in eNOS deficient
mice.
This study was aimed to evaluate the activity of NCX4016, compared to aspirin, on
albuminuria, insulin sensitivity and cardiac and renal hemodynamic in patients with type 2
diabetes mellitus. The patients after one month of placebo treatment, entered two 1-month
treatments periods, with equivalent doses (800 mg of NCX4016, 325 mg of aspirin) of NCX4016
or aspirin.
Nitric oxide-releasing, non-steroidal anti-inflammatory drugs (NO-NSAIDs) are new chemical
entities obtained by adding a nitric oxide-releasing moiety to the parent NSAID via a
short-chain ester linkage. NCX4016 (Nitro-aspirin), a acetoxy-benzoate
2-(2-nitroxymethyl)-phenyl ester of acetylsalicylic acid, is one of these novel compounds
developed with the dual aim to expand the pharmacological properties of the parent drug and
to spare some of its side effects, in particular on the gastrointestinal mucosa. Decreased
NO synthesis may contribute to some of the abnormalities associated with diabetes such as
decreased insulin activity, impaired endothelium-dependent/insulin-induced vasodilatation,
increased sympathetic vasoconstrictor outflow and increased platelet activation, that may
result in increased vascular resistance and arterial hypertension and, in the long term, to
an increased risk of micro- and macrovascular complications.
Low-dose aspirin represents the antiplatelet drug of choice for prevention of vascular
complications in diabetes. Preclinical data on NCX4016 support the possibility that
Nitro-aspirin may shear with aspirin the antithrombotic activity and may offer the
additional benefits related to increased NO bioavailability. Actually NCX4016 inhibits
cyclooxygenase (COX) activity in platelets both in vitro and ex vivo and, similar to
aspirin, prevents the release of thromboxane (TX) A2 and arachidonic acid-induced platelet
aggregation. Moreover Nitro-aspirin inhibits aspirin-insensitive platelet aggregation and
adhesion, possibly by inhibiting the expression of platelet adhesion molecules by a specific
COX-independent mechanism, probably NO-mediated, that is not show by the parent compound.
Therefore Nitro-aspirin can exceed the cardioprotective action of the parent compound, by
adding the aspirin-like moiety and the NO-releasing moiety, which both contribute to its
benefits effects, such as multiple anti-thrombotic and, possibly, anti-atherosclerotic
activities, restoration of insulin-related metabolic and vascular effect and finally blood
pressure reduction. Moreover, experimental and clinical data suggest that Nitro-aspirin will
offer significant safety advantages by its NO moiety that may limit aspirin gastrotoxicity
by preventing the vasocontriction of the mucosal microvasculature.
In the present randomised, double-blind, cross-over study, we evaluated the efficacy and
safety profile of Nitro-aspirin (800 mg bid), and of an equiactive dose of aspirin (325 mg
od), as compared to placebo, in thirteen patients with type 2 diabetes and micro or
macro-albuminuria (overnight albumin excretion rate > 20 µg/min for at least 6 months),
without overt renal insufficiency (serum creatinine concentration < 2 mg/dl) and no specific
controindication to aspirin therapy. Eligible patients who provided written informed
consent, withdrew any previous treatment with NSAIDs or aspirin and, after a 4-week placebo
run-in period, entered two consecutive 4-week treatment periods with Nitro-aspirin plus
aspirin placebo or Nitro-aspirin placebo plus aspirin in a random order. Primary efficacy
variables were changes in urinary albumin excretion (UAE) and in insulin activity at the end
of Nitro-aspirin treatment as compared to baseline. UAE (mean of three overnight urine
collection), insulin sensitivity (glucose disposal rate as measured by an hyperinsulinemic
euglycemic clamp), cardiac haemodynamics (evaluated by echocardiography), NO bioavailability
and oxidative stress (measured as nitrite/nitrate plasma levels) and other clinical and
laboratory variables, were measured at baseline and at the end of each treatment periods.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |